Fungal infections after bone marrow transplant

Biology of Blood and Marrow Transplantation

Volumn 5, Issue 2, 1999, Pages 55-68

  Wingard, J R ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Antifungal agents; Fungal infections; Hematopoietic cell transplant

Indexed keywords

ANTIFUNGAL AGENT;

BONE MARROW TRANSPLANTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MYCOSIS; REVIEW;

ANTIFUNGAL AGENTS; BONE MARROW TRANSPLANTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MYCOSES;

EID: 0032604256     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1053/bbmt.1999.v5.pm10371357     Document Type: Article

References (171)

1. Calderone RA, Braun PC: Adherence and receptor relationships of Candida albicans. Microbiol Rev 55:1, 1991.
2. Cutler JE: Putative virulence factors of Candida albicans. Annu Rev Microbiol 45:187, 1991.
3. Perfect JR: Fungal virulence genes as targets for antifungal chemotherapy. Antimicrob Agents Chemother 40:1577, 1996.
4. Zimmerman LE: Fatal fungus infections complicating other diseases. Am J Clin Pathol 25:46, 1955.
5. Craig JM, Farber S: Development of disseminated visceral mycosis during therapy for acute leukemia. Am J Pathol 29:601, 1953. [abstr]
6. Gerson SL, Talbot GH, Hurwitz S, Stom BL, Lusk EJ, Cassileth PA: Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann Intern Med 100:345, 1984.
7. Jantunen E, Ruutu P, Hiskanen L, Volin L, Parkkali T, Koukila-Kahkola P, Ruutu T: Incidence and risk factors for invasive fungal infections in allogeneic BMT patients. Bone Marrow Transplant 19:801, 1997.
8. Wald A, Leisenring W, van Burik J-A, Bowden RA: Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 175:1459, 1997.
9. Bow EJ, Loewen R, Cheong MS, Schacter B: Invasive fungal disease in adults undergoing remission-induction therapy for acute myeloid leukemia: the pathogenetic role of the antileukemic regimen. Clin Infect Dis 21:361, 1995.
10. Bow EJ, Cheong MS, Shore TB, Rubinger M, Schacter B: Cytotoxic therapy-induced D-Xylose malabsorption and invasive infection during remission-induction therapy for acute myeloid leukemia in adults. J Clin Oncol 15:2254, 1997.
11. Meyers JD: Fungal Infections in bone marrow transplant patients. Semin Oncol 17:10, 1990.
12. Wingard JR, Beals SU, Santos GW, Merz WG, Saral R: Aspergillus infections in bone marrow transplant recipients. Bone Marrow Transplant 2:175, 1987.
13. Sayer HG, Longton G, Bowden R, Pepe M, Storb R: Increased risk of infection in marrow transplant patients receiving methylprednisolone for graft-vs-host disease prevention. Blood 84:1328, 1994.
14. Ochs L, Shu XO, Miller J, Enright H, Filipovich A, Miller W, Weisdorf D: Late infections after allogeneic bone marrow transplantation: comparison of incidence in related and unrelated donor transplant recipients. Blood 86:3979, 1995.
15. Pirsch JD, Maki DG: Infectious complications in adults with bone marrow transplantation and T-cell depletion of donor marrow. Ann Intern Med 104:619, 1986.
16. Robertson MJ, Larson RA: Recurrent fungal penumonias in patients with acute non-lymphoblastic leukemia undergoing multiple courses of intensive chemotherapy. Am J Med 84:233, 1988.
17. Offner F, Cordonnier C, Ljungman P, Prentice HG, Engelhard D, De Bacquer D, Meunier F, De Pauw B: Impact of previous aspergillosis on the outcome of bone marrow transplantation. Clin Infect Dis 26:1098, 1998.
18. Cordonnier C, Beaune J, Offner F, Marinus A, Ljungman P, Neunier F: Aspergillosis prior to BMT. Bone Marrow Transplant 16:323, 1992.
19. Robinson LA, Reed EC, Galbraith TA, Alonso A, Moulton AL, Fleming WH: Pulmonary resection for invasive aspergillus infections in immunocompromised hosts. J Thorac Cardiovasc Surg 109:1182, 1995.
20. Goodrich JM, Reed EC, Mori M, Fisher LD, Skerrett S, Dandliker PS, Klis B, Counts GW, Meyers JD: Clinical features and analysis of risk factors for invasive candidal infection after marrow transplantation. J Infect Dis 164:731, 1991.
21. Tollemar J, Ringden O, Bostrom L, Nilsson B, Sundberg B: Variables predicting deep fungal infections in bone marrow transplant recipients. Bone Marrow Transplant 4:635, 1989.
22. Guiot HFL, Fibbe WE, van't Wout JW: Risk factors for fungal infection in patients with malignant hematologic disorders: implications for empirical therapy and prophylaxis. Clin Infect Dis 18:525, 1994.
23. Morrison VA, Haake RJ, Weisdorf DJ: Non-Candida fungal infections after bone marrow transplantation: risk factors and outcome. Am J Med 96:497, 1994.
24. Wingard JR: Importance of Candida species other than C albicans as pathogens in oncology patients. Clin Infect Dis 20:115, 1995.
25. Morrison VA, Haake RJ, Weisdorf DJ: The spectrum of non-candida fungal infections following bone marrow transplantation. Medicine 72:78, 1993.
26. Wingard JR: Changes in the spectrum of fungal infections in bone marrow transplant patients. Infec Dis Clin Prac 3:S83, 1994.
27. Wingard JR: Opportunistic infections after blood and marrow transplantation. Transplant Infect Dis, 1998. In press.
28. Sanchez V, Vazquez JA, Barth-Jones D, Dembry L, Sobel JD, Zervos MJ: Epidemiology of nosocomial acquisition of Candida lusitaniae. J Clin Microbiol 30:3005, 1992.
29. Sanchez V, Barth-Jones D, Sobel JD: Nosocomial acquisition of Candida parapsilosis: an epidemiologic study. Am J Med 94:577, 1993.
30. Vazquez JA, Sanchez V, Dmuchowski C, Dembry LM, Sobel JD, Zervos MJ: Nosocomial acquisition of Candida albicans: an epidemiologic study. J Infect Dis 168:195, 1993.
31. Van Belkum A, Mol W, van Saene R, Ball LM, van Velzen D, Quint W: PCR-mediated genotyping of Candida albicans strains from bone marrow transplant patients. Bone Marrow Transplant 13:811, 1994.
32. Rangel-Frausto MS, Martin MA, Saiman L, Paterson JE, Pfaller MA, Wenzel RP, and the NEMIS Study Group: High-prevalence of Candida spp. on hands of health care workers in surgical and neonatal intensive care units: a multicenter study. Proceedings 34th Interscience Conference on Antimicrobial Agents and Chemotherapy 1:105, 1994. [abstr]
33. Vazquez JA, Dembry LM, Sanchez V, Vazquez MA, Sobel JD, Dmuchowski C, Zervos MJ: Nosocomial Candida glabrata colonization: an epidemiologic study. J Clin Microbiol 36:421, 1998.
34. Radford SA, Johnson EM, Leeming JP, Millar MR, Cornish JM, Foot AB, Warnock DW: Molecular epidemiological study of Aspergillus fumigatus in a bone marrow transplantation unit by PCR amplification of ribosomal intergenic spacer sequences. J Clin Microbiol 36:1294, 1998.
35. Pfaller MA: Epidemiology of fungal infections: the promise of molecular typing. Clin Infect Dis 20:1535, 1995.
36. Pfaller MA, Herwaldt LA: The clinical microbiology laboratory and infection control: emerging pathogens, antimicrobial resistance, and new technology. Clin Infect Dis 25:858, 1997.
37. Sherertz RJ, Belani A, Kramer BS, Elfenbein GJ, Weiner RS, Sullivan ML, Thomas RG, Samsa GP: Impact of air filtration on nosocomial aspergillus infections: unique risk of bone marrow transplant recipients. Am J Med 83:709, 1987.
38. Withington S, Chambers ST, Beard ME, Inder A, Allen JR, Ikram RB, Schousboe MI, Heaton DC, Spearing RI, Hart DN: Invasive aspergillosis in severely neutropenic patients over 18 years: impact of intranasal amphotericin B and HEPA filtration. J Hospital Infect 38:11, 1998.
39. Passweg JR, Rowlings PA, Atkinson KA, Barrett AJ, Gale RP, Gratwobl A, Jacobsen N, Klein JP, Ljungman P, Russell JA, Schaefer UW, Sobocinski KA, Vossen Jm, Zhang M-J, Horowitz MM: Influence of protective isolation on outcome of allogeneic bone marrow transplantation for leukemia. Bone Marrow Transplant 21:1231, 1998.
40. Pestalozzi BC, Krestin GP, Schanz U, Jacky E, Gmur J: Hepatic lesions of chronic disseminated Candidiasis may become invisible during neutropenia. Blood 90:3858, 1997.
41. Gerson SL, Talbot GH, Lusk E, Hurwitz S, Strom BL, Cassileth PA: Invasive pulmonary aspergillosis in adult acute leukemia: clinical clues to its diagnosis. J Clin Oncol 3:1109, 1985.
42. Gerson SL, Talbot GH, Hurwitz S, Strom BL, Cassileth PA: Discriminant scorecard for diagnosis of invasive pulmonary aspergillosis in patients with acute leukemia. Am J Med 79:57, 1985.
43. Kuhlman JE, Fishman EK, Burch PA, Karp JE, Zerbouni EA, Siegelman SS: Invasive pulmonary aspergillosis in acute leukemia: the contribution of CT to early diagnosis and aggressive management. Chest 92:95, 1987.
44. Drakos PE, Nagler A, Or R, Naparstek E, Kapelushnik J, Engelhard D, Rahav G, Ne'emean D, Slavin S: Invasive fungal sinusitis in patients undergoing bone marrow transplantation. Bone Marrow Transplant 12:203, 1993.
45. Gussack GS, Burson JG, Hudgins P, Wingard JR, Devine SM, York RC, Grist WJ: Sinusitis in the bone marrow transplant patient: diagnosis and management. Am J Rhinology 9:1, 1995.
46. Allo MD, Miller J, Townsend T, Tan C: Primary cutaneous aspergillosis associated with Hickman intravenous catheters. N Engl J Med 317:1105, 1987.
47. Hagensee JE, Bauwens JE, Kjos B: Brain abscess following marrow transplantation: experience at the Fred Hutchinson Cancer Research Center, 1984-1992. Clin Infect Dis 19:402, 1994.
48. Walsh TJ: Role of surveillance cultures in prevention and treatment of fungal infections. NCI Monogr 9:43, 1990
49. Pfaller M, Cabezudo I, Koontz F, Bale M, Gingrich R: Predictive value of surveillance cultures for systemic infection due to Candida species. Eur J Clin Microbiol 6:628, 1987.
50. Aisner J, Murillo J, Schimpff SC, Steere AC: Invasive aspergillosis in acute leukemia: correlation with nose cultures and antibiotic use. Ann Intern Med 90:4, 1979.
51. Sandford GR, Merz WG, Wingard JR, Charache P, Saral R: The value of fungal surveillance cultures as predictors of systemic fungal infections. J Infect Dis 142:503, 1980.
52. Uxun O, Anaissie EJ: Antifungal prophylaxis in patients with hematologic malignancies: a reappraisal. Blood 86:2063, 1995.
53. Walsh TJ, Merz WG, Lee JW, Schaufele R, Sein T, Whitcomb PO, Ruddel M, Burns W, Wingard JR, Switchenko AC, Goodman T, Pizzo PA: Diagnosis and therapeutic monitoring of invasive candidiasis by rapid enzymatic detection of serum D-arabinitol. Am J Med 99:164, 1995.
54. Holmes AR, Cannon RD, Shepherd MG, Jenkinson HF: Detection of Candida albicans and other yeasts in blood by PCR. J Clin Microbiol 32:228, 1994.
55. Fujita SI, Lasker BA, Lott TJ: Microtitration plate enzyme immunoassay to detect PCR-amplified DNA from Candida species in blood. J Clin Microbiol 33:962, 1995.
56. Einsele H, Hebart H, Roller G, Loffler J, Rothenhofer I, Muller CA, Bowden RA, ran Burik J, Engelhard D, Kanz L, Schumacher U: Detection and identification of fungal pathogens in blood by using molecular probes. J Clin Microbiol 35:1353, 1997.
57. Stynen D, Goris A, Sarfati J, Latge JP: A new sensitive sandwich enzyme-linked immunosorbent assay to detect galactofuran in patients with invasive aspergillosis. J Clin Microbiol 33:497, 1995.
58. Verweij PE, Rijs AJMM, De Pauw BE, Horrevorts AM, Hoogkamp-Korstanje JA, Meis JF: Clinical evaluation and reproducibility of the pastorex aspergillus antigen latex agglutination test for diagnosing invasive aspergillosis. J Clin Pathol 48:474, 1995.
59. Verweij PE, Stynen D, Rijs AJMM, de Pauwv BE, Hoogkamp-Korstanje JAA, Meis JFGM: Sandwich enzyme-linked immunosorbent assay compared with pastorex latex agglutination test for diagnosing invasive aspergillosis in immunocompromised patients. J Clin Microbiol 33:1912, 1995.
60. Verweij PE, Latge JP, Rijs AJMM, Melchers WJG, de Pauw BE, Hoogkamp-Korstanje JAA, Meis JFGM: Comparison of antigen detection and PCR assay using bronchoalveolar lavage fluid for diagnosing invasive pulmonary aspergillosis in patients receiving treatment for hematological malignancies. J Clin Microbiol 33:3150, 1995.
61. Patterson TF, Miniter P, Patterson JE, Rappeport JM, Andriole VT: Aspergillus antigen detection in the diagnosis of invasive aspergillosis. J Infect Dis 171:1553, 1995.
62. Spreadbury C, Holden D, Aufauvre-Brown A, Bainbridge B, Cohen J: Detection of Aspergillus fumigatus by polymerase chain reaction. J Clin Microbiol 31:615, 1993.
63. Loffler J, Hebart H, Schumacher U, Reitze H, Einsele H: Comparison of different methods for extraction of DNA of fungal pathogens from cultures and blood. J Clin Microbiol 35:2211, 1997.
64. Groll AH, Piscitelli SC, Walsh TJ: Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Adv Pharmacol 44:343, 1998.
65. Fryberg M, Oehlschlager AC, Unrau AM: Sterol biosynthesis in antibiotic sensitive and resistant Candida. Arch Biochem Biophys 173:171, 1975.
66. Dick JD, Merz WG, Saral R: Incidence of polyene-resistant yeasts recovered from clinical specimens. Antimicrob Agents Chemother 18:158, 1980.
67. Bossche HV, Marical P, Odds FC: Molecular mechanisms of drug resistance in fungi. Trends Microbiol 2:392, 1994.
68. Merz WG: Candida lusitaniae: frequency of recovery, colonization, infection, and amphotericin B resistance. J Clin Microbiol 20:1194, 1984.
69. Wingard JR, Kubilis P, Lee L, Yee G, White M, Walshe L, Bowden R, Anaissie E, Hiemenz J, Lister J: Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Blood 92 (Suppl 1):518a, 1998. [abstr]
70. Hiemenz JW, Walsh TJ: Lipid formulations of amphotericin B: recent progress and future directions. Clin Infect Dis 22:S133, 1996.
71. Tollemar J, Ringden O: Lipid formulations of amphotericin B: less toxicity but at what economic cost? Drug Safety 13:207, 1995.
72. Wong-Beringer A, Jacobs RA, Guglielmo BJ: Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin Infect Dis 27:603, 1998.
73. Boswell GW, Buell D, Bekersky I: AmBisome (liposomal amphotericin B): a comparative review. J Clin Pharmacol 38:583, 1998.
74. Dix SP, Wingard JR: Amphotericin B lipid complex: review of safety, pharmacokinetics and efficacy. Drugs Today 32:411, 1996.
75. Hiemenz JW, Lister J, Anaissie EJ, White MH, Dinuble M, Silber J, Horwith G, Lee LW: Emergency-use Amphotericin B Lipid Complex (ABLC) in the treatment of patients with aspergillosis: historical-control comparison with amphotericin B. Blood 86:848a, 1995. [abstr]
76. White MH, Kusne S, Wingard JR, Hiemenz JW, Cantor A, Gurwith M, DuMond C, Mamelok RD, Bowden RA: Amphotericin B colloidal dispersion versus amphotericin B in the therapy of invasive aspergillosis. Clin Infect Dis 24:635, 1997.
77. Anaissie EJ, White M, Uzun O, Singer C, Godey GP, Matzke D, Azarnia N, Lopez-Berestein G: Amphotericin B lipid complex (ABLC) versus amphotericin B (AMB) for treatment of hematogenous and invasive candidiasis: a prospective, randomized, multicenter trial. Proceedings 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, 330, 1995. [abstr]
78. Bowden R, Chandrasekar P, White M, Wingard J, and the Multicenter Aspergillus Study Group: A double-blind, randomized controlled trial of amphocil (ABCD) vs. amphotericin B (AmB) for treatment of invasive aspergillosis in immunocompromised patients. 10th International Symposium on Infection in the Immunocompromised Host, June 21-24, Davos, Switzerland.
79. Conneally E, Cafferkey MT, Daly PA, Keane CT, McCann SR: Nebulized amphotericin B as prophylaxis against invasive aspergillosis in granulocytopenic patients. Bone Marrow Transplant 5:403, 1990.
80. Beyer J, Barzen G, Risse G, Weyer C, Kiksits K, Dullenkopf K, Huhn D, Siegert W: Aerosol amphotericin B for prevention of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 37:1367, 1993.
81. Myer SE, Devine SM, Topper RL, Ondrey M, Chandler C, O'Toole K, Williams SF, Larson RA, Geller RB: A pilot study of prophylactic aerosolized amphotericin B in patients at risk for prolonged neutropenia. Leuk Lymphoma 8:229, 1992.
82. Schwartz S, Beyer J, Behre G, Lenz K, Wandt H, Gruneisen A, Trittin A, Thiel E: Evaluation of aerosol amphotericin B for prophylaxis of invasive pulmonary aspergillosis in neutropenic patients - an interim analysis of a prospective, randomized trial. Blood 84:306a, 1994. [abstr]
83. Rex JH, Bennett JE, Sugar AM, Pappas PG, van der Horst CM, Edwards JE, Washburn RG, Scheld WM, Karchmer AW, Dine AP, Levenstein MJ, Webb CD: A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 331:1325, 1994.
84. Anaissie EJ, Vartivarian SE, Abi-Said D, Uzun O, Pinczowski H, Kontoyiannis DP, Khoury P, Papadakis K, Gardner A, Raad IIl, Gilbreath J, Bodey GP: Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study. Am J Med 101:170, 1996.
85. Tricot G, Joosten E, Boogaerts MA, Vande Pitte J, Cauwenbergh G: Ketoconazole versus itraconazole for antifungal prophylaxis in patients with severe granulocytopenia: preliminary results of two nonrandomized studies. Rev Inf Dis 9:94, 1987.
86. Boogaerts MA, Verhoef GE, Zachee P, Demuynck H, Vergist L, De Beule K: Antifungal prophylaxis with itraconazole in prolonged neutropenia: correlation with plasma levels. Mycoses 32:103, 1989.
87. Persan F, Marzullo C, Guyotat D: Plasma itraconazole concentrations in neutropenic patients after repeated high-dose treatment. Eur J Cancer 28A:838, 1992.
88. Hostetler JS, Hanson LH, Stevens DA: Effect of cyclodextrin on the pharmacology of antifungal oral azoles. Antimicrob Agents Chemother 36:477, 1992.
89. Prentic AG, Wernock DW, Johnson SAN, Phillips MJ, Oliver DA: Multiple dose pharmacokinetics of an oral solution of itraconazole in autologous bone marrow transplant recipients. J Antimicrob Chemother 34:247, 1994.
90. Michallet M, Persat F, Kranzhofer N, Levron J-C, Prat C, Belhabri A, Chwetzoff E, Le Moing J-P, Fiere D, Piens M-A: Pharmacokinetics of itraconazole oral solution in allogeneic bone marrow transplant patients receiving total body irradiation. Bone Marrow Transplant 21:1239, 1998.
91. Orozco AS, Higginbotham LM, Hitchcock CA, Parkinson T, Falconer D, Ibrahim AS, Ghannoum MA, Filler SG: Mechanism of fluconazole resistance in Candida krusei. Antimicrob Agents Chemother 42: 2645, 1998.
92. Venkateswarlu K, Denning DW, Manning NJ, Kelly SL: Reduced accumulation of drug in Candida krusei accounts for itraconazole resistance. Antimicrob Agents Chemother 40:2443, 1996.
93. Nolte FS, Parkinson T, Falconer DJ, Dix S, Williams J, Gilmore C, Geller RB, Wingard JR: Isolation and characterization of fluconazole- and amphotericin B-resistant Candida albicans from blood of two patients with leukemia. Antimicrob Agents Chemother 41:196, 1997.
94. Marr KA, White TC, van Burik J-AH, Bowden RA: Development of fluconazole resistance in Candida albicans causing disseminated infection in a patient undergoing marrow transplantation. Clin Infect Dis 25:908, 1997.
95. Alexander BD, Perfect JR: Antifungal resistance trends towards the year 2000. Implications for therapy and new approaches. Drugs 54:657, 1997.
96. Denning DW, Baily GG, Hood SV: Azole resistance in Candida. Eur J Clin Microbiol Infect Dis 16:261, 1997.
97. Hitchcock CA, Pye GW, Oliver GP, et al: UK 109496, a novel wide spectrum triaderivative for the treatment of fungal infections: antifungal activity and selectivity in vitro. Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 125, 1995. [abstr]
98. Radford SA, Johnson EM, Warnock DW: In vitro studies of activity of voriconazole (UK 109496), a new triazole antifungal agent, against emerging and less common mold pathogens. Antimicrob Agents Chemother 41:841, 1997.
99. McGinnis MR, Pasarell L, Cooper CR: In vitro susceptibility of clinical mould isolates to UK 109496. Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 99, 1995. [abstr]
100. Oakley KL, Moore CD, Denning DW: In-vitro activity of voriconazole against Aspergillus spp. and comparison with itraconazole and amphotericin B. J Antimicrob Chemother 42:91, 1998.
101. Troke PF, Brammer KW, Hitchcock CA, Yonren S, Sarantis N: UK 109496, a novel wide spectrum triazole derivative for the treatment of fungal infections: activity in systemic candidiasis models and early clinical efficacy in oropharyngeal candidiasis (OPC). Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1995. 125, [abstra]
102. Denning D, del Favero A, Gluckman E, Norfolk D, Ruhnke M, Yonren S, Troke P, Sarantis N: A novel, wide-spectrum triazole derivative for the treatment of fungal infections: clinical efficacy in acute invasive aspergillosis. Proceedings 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, 126, 1995. [abstr]
103. Denning D, DelFavero A, Gluckman E, Norfolk D, Ruhnke M, Yonren S, Troke P, Sarantis N: UK 109496, a novel wide spectrum triazole derivative for the treatment of fungal infections: clinical efficacy in acute invasive aspergillosis. Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 126, 1995. [abstr]
104. Dupont B, Denning D, Lode H, Yonren S, Troken P, Sarantis N: UK 109496, a novel wide spectrum triazole derivative for the treatment of fungal infections: clinical efficacy in chronic invasive aspergillosis. Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 127, 1995. [abstr]
105. Cacciapuoti A, Parmegiani R, Loebenberg D, Antonacci B, Moss EL, Menzel F, Norris C, Hare RS, Miller GH: Efficacy of SCH 56592 in pulmonary aspergillosis and candidiasis in mice. Proceedings 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, 124, 1995. [abstr]
106. Pfaller MA, Messer S, Jones RN: Activity of a new triazole, SCH56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae. Antimicrob Agents Chemother 41:233, 1997.
107. Dupont B, Improvisi L, Dromer F: In vitro and in vivo activity of a new antifungal agent SCH56592. Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 116, 1996. [abstr]
108. Sugar AM, Liu XP: In vitro and in vivo activities of SCH 56592 against Blastomyces dermatitidis. Antimicrob Agents Chemother 40:1314, 1996.
109. Law D, Moore CB, Denning DW: Activity of SCH 56592 compared with those of fluconazole and itraconazole against Candida spp. Antimicrob Agents Chemother 41:2310, 1997.
110. Oakley KL, Morrissey G, Denning DW: Efficacy of SCH 56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-susceptible and an itraconazole-resistant isolate of Aspergillus fumigatus. Antimicrob Agents Chemother 41:1504, 1997.
111. Denning DW: Echinocandins and pneumocandins - a new antifungal class with a novel mode of action. J Antimicrob Chemother 40:611, 1997.
112. Fung-Tomc JC, Minassian B, Huczko E, Kolek B, Bonner DP, Kessler RE: In vitro antifungal and fungicidal spectra of a new pradimicin derivative, BMS-181184. Antimicrob Agents Chemother 39:295, 1995.
113. Mehta RT, Hopfer RL, McQueen T, Juliano RL, Lopez-Berestein G: Toxicity and therapeutic effects in mice of liposome-encapsulated nystatin for systemic fungal infections. Antimicrob Agents Chemother 31:1901, 1987.
114. Boutati E, Maltezou HC, Lopez-Berestein G, Vartivarian SE, Anaissie EJ: Phase I study of maximum tolerated dose of intravenous liposomal nystatin for the treatment of refractory febrile neutropenia in patients with hematological malignancies. Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 330, 1995. [abstr]
115. Hector RF, Schaller K: Positive interaction of nikkomycins and azoles against Candida albicans in vitro and in vivo. Antimicrob Agents Chemother 36:1284, 1992.
116. Flores ME, Hector RF: In vitro activity of the antifungal nikkomycin Z (SP-920704) in combination with fluconazole or itraconazole vs. yeasts. Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 133, 1996. [abstr]
117. Wingard JR, Vaughan WP, Braine HG, Merz WG, Saral R: Prevention of fungal sepsis in patients with prolonged neutropenia: a randomized, double-blind, placebo-controlled trial of intravenous miconazole. Am J Med 83:1103, 1987.
118. Goodman JL, Winston DJ, Greenfield RA: A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 326:845, 1992.
119. Slavin MA, Osborne B, Adams R, Levenstein MJ, Schoch HG, Fledman AR, Meyers JD, Bowden RA: Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomized, double-blind study. J Infect Dis 171:1545, 1995.
120. Hansen JA, Gooley TA, Martin PJ, Appelbaun F, Chauncey TR, Clift RA, Petersdorf EW, Radich J, Sanders JE, Storb RF, Sullivan KM, Anasetti C: Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med 338:962, 1998.
121. Ninane J, and a Multicentre Study Group: A multicentre study of fluconazole versus oral polyenes in the prevention of fungal infection in children with hematological or oncological malignancies. Eur J Clin Microbiol Infect Dis 13:330, 1994.
122. Ellis ME, Clink H, Halim MA, Padmos A, Spence D, Kalink M, Hussain Qadri SM, Burnie J, Greer W: Controlled study of fluconazole in the prevention of fungal infections in neutropenic patients with haematological malignancies and bone marrow transplant recipients. Eur J Clin Microbiol Infect Dis 13:3, 1994.
123. Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R: Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 325:1274, 1992.
124. Persons DA, Laughlin M, Tanner D, Perfect J, Gockerman JP, Hathorn JW: Fluconazole and Candida krusei fungemia. N Engl J Med 325:1315, 1991. [letter]
125. Wingard JR, Merz WG, Rinaldi MG, Miller CB, Karp JE, Saral R: Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob Agents Chemother 37:1847, 1993.
126. DuBois D, van Burik J-A, Davis C, et al: Emergence of non-Candida albicans fungemia in bone marrow transplant (BMT) patients receiving fluconazole (FLU) prophylaxis. Proceedings 34th Interscience Conference on Antimicrob Agents and Chemother 1:9, 1994. [abstr]
127. Girmenia C, Martino P, Cassone A: Breakthrough candidemia during antifungal treatment with fluconazole in patients with hematologic malignancies. Blood 87:838, 1996.
128. Vreugdenhil G, Van Dijke BJ, Donnelly P, Novakova IRO, Raemaekers JMM, Koogkamp-Korstanje MAA, Koster M, de Pauw BE: Efficacy of itraconazole in the prevention of fungal infections among neutropenic patients with hematologic malignancies and intensive chemotherapy: a double-blind, placebo controlled study. Leuk Lymphoma 11:353, 1993.
129. Michailov G, Laporte JP, Lesage S, Fouillard L, Isnard F, Noel-Walter MP, Jouiet JP, Najman A, Gorin NC: Autologous bone marrow transplantation is feasible in patients with a prior history of invasive pulmonary aspergillosis. Bone Marrow Transplant 17:569, 1996.
130. Richard C, Romon I, Baro J, Unsunza A, Loyola I, Zurbano F, Tapin M, Iriondo A, Conde E, Zubizarreta A: Invasive pulmonary aspergillosis prior to BMT in acute leukemia patients does not predict a poor outcome. Bone Marrow Transplant 12:237, 1993.
131. Martino R, Mondedeu J, Altes A, Sureda A, Brunet S, Martinez C, Domingo-Albos A: Successful bone marrow transplantation in patients with previous invasive fungal infections: Report of four cases. Bone Marrow Transplant 13:265, 1994.
132. Michailov G, Laporte JPH, Lesage S, Fouillard L, Isnard F, Noel-Walter MP, Jouiet JP, Najman A, Gorin NC: Autologous bone marrow transplantation is feasible in patients with a prior history of invasive pulmonary aspergillosis. Bone Marrow Transplant 17:569, 1996.
133. Cordonnier C, Beaune J, Offner F, Marinus A, Ljungman P, Meunier F: Aspergillosis prior to bone marrow transplantation. Bone Marrow Transplantation 16:323, 1995.
134. Denning DW, Stevens DA: Antifungal and surgical treatment of invasive aspergillosis: a review of 2,121 published cases. Rev Infect Dis 12:1147, 1990.
135. Salerno CT, Ouyang DW, Pederson TS, Larson DM, Shake JP, Johnson EM, Maddaus MA: Surgical therapy for pulmonary aspergillosis in immunocompromised patients. Ann Thorac Surg 65:1415, 1998.
136. Rousey SR, Russler S, Gottlieb M, Klotman ME, Goris A: Low-dose amphotericin B prophylaxis against invasive aspergillus infections in allogeneic marrow transplantation. Am J Med 91:484, 1991.
137. O'Donnell MR, Schmidt GM, Tegtmeier BR, Vaucett C, Fahey JL, Ito J, Nademanee A, Niland J, Parker P, Smith EP, Snyder DS, Stein AS, Blume KG, Forman SJ: Prediction of systemic fungal infection in allogeneic marrow recipients: impact of amphotericin prophylaxis in high-risk patients. J Clin Oncol 12:827, 1994.
138. Riley DK, Pavia AT, Beatty PG, Peterson FB, Spruance JL, Stokes R, Evans TG: The prophylactic use of low-dose amphotericin B in bone marrow transplant patients. Am J Med 97:509, 1994.
139. Perfect JR, Klotman ME, Gilbert CC, Crawford DD, Rosner GL, Wright KA, Peters WP: Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients. J Infect Dis 165:891, 1992.
140. Dick JD, Merz WG, Saral R: Incidence of polyene-resistant yeasts recovered from clinical specimens. Antimicrob Agents Chemother 18:158, 1980.
141. Tollemar J, Ringden O, Andersson S, Sundberg B, Ljungman P, Sparrelid E, Tyden G: Prophylactic use of liposomal amphotericin B (AmBisome) against fungal infections: a randomized trial in bone marrow transplant recipients. Transplant Proc 25:1495, 1993.
142. Arroyo J, Medoff G, Kobayashi GS: Therapy of murine aspergillosis with amphotericin B in combination with rifampin or 5-fluorocytosine. Antimicrob Agents Chemother 11:21, 1977.
143. Verfaillie C, Weisdorf D, Haake R, Hostetter M, Ramsay NKC, McGlave P: Candida infections in bone marrow transplant recipients. Bone Marrow Transplant 8:177, 1991.
144. Morrison VA, Haake RJ, Weisdorf DJ: Non-Candida fungal infections after bone marrow transplantation: risk factors and outcome. Am J Med 96:497, 1994.
145. White MH, Bowden RA, Sandler E, Graham ML, Noskin GA, Wingard JR, Goldman M, McCabe A, Lin J-S, Gurwith M, Miller CB: Randomized, double blind clinical trial of Amphotericin B Colloidal dispersion vs amphotericin B in the empiric treatment of fever in neutropenia. Clin Infect Dis 27:296, 1998.
146. Doebbling BN, Dawson JD, Wenzel RP, and the Candidemia Study Group: Determinants of outcome for patients treated for Candidemia: a multicenter study. Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 272, 1995. [abstr]
147. Aoun M, van der Auwera P, Gerain J, Klastersky J: Aspergillosis in the immunocompromised: focus on treatment. Recent Results Cancer Res 132:127, 1993.
148. Ringden O, Andstrom E, Remberger M: Safety of liposomal amphotericin B (AmBisome) in 187 transplant recipients treated with cyclosporin. Bone Marrow Transplant 14 (Suppl 5):S10, 1994.
149. Wingard JR: Efficacy of amphotericin B lipid complex injection (ABLC) in bone marrow transplant recipients with life-threatening systemic mycoses. Bone Marrow Transplant 19:343, 1997.
150. Pizzo PA, Robichaud RN, Gill FA, Witebsky FG: Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 72:101, 1982.
151. EORTC International Antimicrobial Therapy Cooperative Group: Empiric antifungal therapy in febrile granulocytopenic patients. Am J Med 86:668, 1989.
152. Walsh T, Bodensteiner D, Hiemenz J: AmBisome (liposomal amphotericin B) versus conventional amphotericin B in treating febrile neutropenic patients. Selected Abstract Summaries and Comment from the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 1997. [abstr]
153. Boogaerts M, Tormans G, Maes E, van Doorslaer B: Cost-effectiveness of analysis of AmBisome (AMB) vs. Amphotericin B (AMPHOB) in the empiric treatment of febrile neutropenia in adults and children. Blood 88 (Suppl 1):501a, 1994, 1996. [abstr]
154. Prentice HG, Hann IM, Herbrecht R, Aoun M, Kvaloy S, Catovsky D, Pinkerton CR, Schey SA, Jacobs F, Oakhill A, Stevens RF, Darbyshire PJ, Gibson BE: A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Hematol 98:711, 1997.
155. Clements JS, Peacock JE: Amphotericin B revisited: reassessment of toxicity. Am J Med 88:5N, 1990.
156. Hoitsma AJ, Wetzels FJ, Koene RA: Drug-induced nephrotoxicity. Drug Safety 6:131, 1991.
157. Kennedy MS, Joachim D, Siegel M, Crowley JJ, Storb R, Thomas ED: Acute renal toxicity with combined use of amphotericin B and cyclosporine after marrow transplantation. Transplantation 35:211, 1983.
158. Wingard JR: Growth Factors and other immunomodulators. In R Bowden, P Ljungman, C Paya (eds) Transplant Infections. Philadelphia, PA: Lippincott Raven, 367, 1997.
159. Bensinger WI, Price TH, Dale DC, Appelbaum FR, Clift R, Lilleby K, Williams B, Storb R, Thomas ED, Buckner CD: The effects of daily recombinant human granulocyte colony-stimulating factor administration on normal granulocyte donors undergoing leukapheresis. Blood 81:1883, 1993.
160. Feldman E, Hester J, Vartivarian S: The use of granulocyte-colony stimulating factor (G-CSF) enhanced granulocyte transfusions from normal donors in patients (pts) with neutropenia-related fungal infections. Proceedings of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, September-October 1993. Washington, DC: American Society for Microbiology. [abstr]
161. Casper CB, Seger RA, Burger J, Gmur J: Effective stimulation of donors for granulocyte transfusions with recombinant methionyl granulocyte colony-stimulating factor. Blood 81:2866, 1993.
162. Rex JH, Bennett JE, Gallin JI, Malech HL, DeCarlo ES, Melnick DA: In vivo interferon-gamma therapy augments the in vitro ability of chronic granulomatous disease neutrophils to damage aspergillus hyphae. J Infect Dis 163:849, 1991.
163. Housley RM, Morris CF, Boyle W, Ring R, Biltz R, Tarpley JE, Aukerman SL, Devine PL, Whitehead RH, Pierce GF: Keratinocyte growth factor induced proliferation of hepatocytes and epithelial cells throughout the rat gastrointestinal tract. J Clin Invest 94:1764, 1994.
164. Yi ES, Shabaik AS, Lacey DL, Bedoya AA, Yin S, Housley RM, Danilenko MD, Benson W, Cohen AM, Pierce GF, Thomaason A, Ulich TR: Keratinocyte growth factor causes proliferation of urothelium in vivo. J Urol 154:1566, 1995.
165. Yi ES, Yin S, Harclerode DL, Bedoya A, Bikbazi NB, Housley RM, Aukerman SL, Morris CF, Pierce GF, Ulich TR: Keratinocyte growth factor induces pancreatic ductal epithelial proliferation. Am J Pathol 145:80, 1994.
166. Krijanovski OI, Hill GR, Teshima T, Crawford JM, Ferrara JLM: Keratinocyte growth factor (KGF) prevents GVHD and preserves GVL after experimental allogeneic BMT. Blood 92 (Suppl 1):2956, 1998. [abstr]
167. Sonis ST, Lindquist L, Van Vugt A, Stewart AA, Stam K, Quu GY, Iwata KK, Haley JD: Prevention of chemotherapy-induced ulcerative mucositis by transforming growth factor 3. Cancer Res 54:1135, 1994.
168. Booth C, Potten CS: Effects of IL-11 on the growth of intestinal epithelial cells in vitro. Cell Prolif 28:581, 1995.
169. Orazi A, Du X, Yang Z, Kashai M, Williams DA: Interleukin-11 prevents apoptosis and accelerates recovery of small intestinal mucosa in mice treated with combined chemotherapy and radiation. Lab Invest 75:33, 1996.
170. Sonis ST, VanVugt AG, McDonald J, Dotoli E, Schwertschlag U, Szklut P, Keith J: Mitigating effects of Interleukin-11 on consecutive courses of 5-flourouracil-induced ulcerative mucositis in hamsters. Cytokine 9:605, 1997.
171. Karthaus M, Rosenthal C, Huebner G, Paul H, Elser C, Hertenstein B, Krauter J, Scharman, Geissler RG, Heil G, Ganser A: Effect of topical oral G-CSF on oral mucositis: a randomized placebo-controlled trial. Bone Marrow Transplant 22:781, 1998.